Latest Content

Dr. McKenzie explains bile duct cancer subtypes, genomic profiling, targeted therapies and multidisciplinary strategies to improve quality of life.

Dr. Ashkan Emadi outlines eligibility, referral and care logistics for a first-in-world subcutaneous Blincyto trial at WVU Cancer Institute.

A new study suggests that a proactive, tech-driven approach to palliative care can significantly improve the lives of children with advanced cancer.

A patient with cancer reflects on participating in a clinical study and how community and creativity helped ease chemo brain symptoms.

FDA accepted a new drug application for tirabrutinib in relapsed or refractory PCNSL.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

FDA approves Filkri, a biosimilar that helps reduce infection risk and speed white blood cell recovery during chemotherapy and other treatments.

Rising cancer rates in young adults highlight the need for employer support, flexible work and whole-person health programs to improve outcomes.

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial.

The FDA is reviewing iberdomide for relapsed or refractory multiple myeloma, with a decision date set for August.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control.

Five years ago, I finished treatment and was determined to be no evidence of disease. Until my most recent CT scan, there’s been no sign of recurrence.

Black patients were underrepresented in ovarian cancer trials and had lower overall survival than White patients in a pooled analysis of 1,903 participants.